Hollis-Eden compounds show promise in cystic fibrosis

Data presented by the company at the European Cystic Fibrosis Conference in Copenhagen, Denmark, highlight the significant anti-inflammatory activity discovered when each of the five candidate compounds is given orally in mouse models of lung inflammation and septic shock, as judged by reduced levels of pro inflammatory cytokines such as TNF alpha and IL-6 in lung and blood.

Data presented also demonstrate the ability of the compounds to significantly limit pro-inflammatory cytokines in vitro, using human whole blood, and showcase preliminary work in monkeys suggesting the potential for significant oral bioavailability and activity in primates. Studies indicate that none of the compounds is immune suppressive, but rather may actually enhance cellular immune responses.

The company believes that these anti-inflammatory and immune-stimulating properties of its Hormonal Signaling Technology Platform may contribute to a decrease in the chronic lung inflammation associated with cystic fibrosis (CF) and limit and prevent pulmonary infections in CF patients.

The company plans to compare the five compounds in preclinical toxicity studies as well as additional efficacy studies in order to arrive at the optimal compound for continued clinical development.

“This is an important milestone and we are excited about the prospects for developing a safe, orally active agent that can combat the chronic inflammation observed in the CF lung without the unwanted immune suppressive side effects associated with some current treatment options,” said Dr Robert Beall, president and CEO of the CF Foundation.